Latest Breaking News On - Pol theta helicase - Page 2 : comparemela.com

IDEAYA Biosciences (NASDAQ:IDYA – Free Report) had its price objective cut by The Goldman Sachs Group from $53.00 to $46.00 in a report released on Monday, Benzinga reports. They currently have a buy rating on the stock. A number of other research analysts also recently weighed in on the company. Royal Bank of Canada raised […]

Los angelesUnited statesZurcher kantonalbank zurich cantonalbankWerner helicaseBiosciences incGoldman sachs groupAlps advisors incRoyal bankLos angeles capital managementJpmorgan chase coAmeritas investment partners incBiosciences company profileFree reportOne financialGet free reportInvestment partners